Equities research analysts at Needham & Company LLC started coverage on shares of NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) in a note issued to investors on Wednesday, Benzinga reports. The firm set a “buy” rating and a $36.00 price target on the stock. Needham & Company LLC’s target price would indicate a potential upside of 114.67% from the company’s previous close.
Several other research analysts have also commented on NAMS. TD Cowen assumed coverage on shares of NewAmsterdam Pharma in a report on Wednesday, May 15th. They issued a “buy” rating for the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $31.00 target price on shares of NewAmsterdam Pharma in a report on Tuesday, July 30th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, NewAmsterdam Pharma has a consensus rating of “Buy” and a consensus price target of $33.80.
Get Our Latest Report on NewAmsterdam Pharma
NewAmsterdam Pharma Price Performance
NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.08. The firm had revenue of $2.28 million for the quarter, compared to analyst estimates of $2.20 million. On average, equities analysts forecast that NewAmsterdam Pharma will post -2.24 EPS for the current fiscal year.
Insider Buying and Selling at NewAmsterdam Pharma
In other NewAmsterdam Pharma news, CEO Michael H. Davidson bought 5,000 shares of the stock in a transaction that occurred on Thursday, June 20th. The shares were purchased at an average cost of $17.26 per share, for a total transaction of $86,300.00. Following the transaction, the chief executive officer now directly owns 204,784 shares in the company, valued at $3,534,571.84. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 19.50% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Jennison Associates LLC bought a new position in NewAmsterdam Pharma during the first quarter valued at about $22,015,000. Artal Group S.A. bought a new position in shares of NewAmsterdam Pharma during the 1st quarter valued at about $18,920,000. Janus Henderson Group PLC acquired a new position in shares of NewAmsterdam Pharma in the 1st quarter worth approximately $15,018,000. Decheng Capital LLC bought a new stake in shares of NewAmsterdam Pharma in the 2nd quarter worth approximately $7,684,000. Finally, Opaleye Management Inc. acquired a new stake in NewAmsterdam Pharma during the fourth quarter valued at approximately $2,964,000. 89.89% of the stock is currently owned by institutional investors.
NewAmsterdam Pharma Company Profile
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Recommended Stories
- Five stocks we like better than NewAmsterdam Pharma
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Are Utility Stocks Running Out of Steam? What You Need to Know
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Snowflake’s Risk/Reward Profile Is Too Good To Miss
- Business Services Stocks Investing
- Akamai: AI Tailwinds Drive Edge Computing and Security Growth
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.